Dissecting the therapeutic effects of anti-CTLA-4 and ADT in a murine hormone-sensitive prostate cancer

被引：10
|
作者：
Subudhi, Sumit Kumar
Montalvo-Ortiz, Welby
Scher, Howard I.
Allison, James Patrick
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA
[3] Mem Sloan Ketterings Ludwig Ctr Canc Immunotherap, Howard Hughes Med Inst, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.61
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
61
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial
    Bian, Xiaojie
    Gu, Weijie
    Zhang, Xuepei
    Xie, Liping
    Wang, Shaogang
    Shi, Benkang
    Sun, Ting
    Wei, Shaozhong
    Weng, Zhiliang
    Xia, Shujie
    Han, Bangmin
    Xu, Zhuoqun
    Xing, Jinchun
    Zhang, Dahong
    Xu, Danfeng
    Du, Chuanjun
    He, Chaohong
    Wang, Qilin
    Yang, Xinfeng
    Lian, Jianpo
    Wang, Wenliang
    Ye, Dingwei
    MED, 2025, 6 (02):
  • [22] Effects of sorafenib on proliferation of hormone-sensitive and hormone-insensitive prostate cancer cells
    Culig, Z.
    Oh, S. Jung
    Santer, F. R.
    Puhr, M.
    Steiner, H.
    Hobisch, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Merseburger, Axel S.
    Suttmann, Henrik
    AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
  • [24] Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy
    Babamohamadi, Mehregan
    Mohammadi, Nastaran
    Faryadi, Elham
    Haddadi, Maryam
    Merati, Amirhossein
    Ghobadinezhad, Farbod
    Amirian, Roshanak
    Izadi, Zhila
    Hadjati, Jamshid
    CELL DEATH & DISEASE, 2024, 15 (01) : 17
  • [25] Approaches to the treatment of patients with hormone-sensitive prostate cancer
    DiPaola, RS
    SEMINARS IN ONCOLOGY, 1999, 26 (05) : 24 - 27
  • [26] Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer
    Kothari, Gargi
    Ost, Piet
    Cheung, Patrick
    Blanchard, Pierre
    Tree, Alison C.
    van As, Nicholas J.
    Lo, Simon S.
    Moghanaki, Drew
    Loblaw, Andrew
    Siva, Shankar
    CURRENT ONCOLOGY REPORTS, 2019, 21 (05)
  • [27] Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer
    Clement, Jessica M.
    Sweeney, Christopher J.
    JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (01) : 9 - +
  • [28] Diagnosis and staging of metastatic hormone-sensitive prostate cancer
    Krausewitz, Philipp
    Ritter, Manuel
    Essler, Markus
    UROLOGIE, 2023, 62 (04): : 347 - 353
  • [29] Treatment of primary cancer in metastatic hormone-sensitive prostate cancer
    Lim, Kylie Y. -Y.
    Alberto, Matthew
    Ranasinghe, Weranja
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2023, 17 (04) : 315 - 323
  • [30] Neoantigen cancer vaccine augments anti-CTLA-4 efficacy
    Salvatori, Erika
    Lione, Lucia
    Compagnone, Mirco
    Pinto, Eleonora
    Conforti, Antonella
    Ciliberto, Gennaro
    Aurisicchio, Luigi
    Palombo, Fabio
    NPJ VACCINES, 2022, 7 (01)
12345